June 11 (Reuters) - Novartis AG:
* US FDA APPROVES UPDATED NOVARTIS BEOVU® LABEL, TO INCLUDE ADDITIONAL SAFETY INFORMATION
* NOVARTIS IS CONFIDENT THAT BEOVU CONTINUES TO REPRESENT AN IMPORTANT TREATMENT OPTION FOR PATIENTS WITH WET AMD, WITH AN OVERALL FAVORABLE BENEFIT/RISK PROFILE
* UPDATE TO US LABEL INCLUDES ADDITION OF SUB-SECTION DEDICATED TO RETINAL VASCULITIS AND/OR RETINAL VASCULAR OCCLUSION Source text: Further company coverage: (Berlin Speed Desk)
Our Standards: The Thomson Reuters Trust Principles.